(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 15.53% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Ani Pharmaceuticals's revenue in 2026 is $883,366,000.On average, 9 Wall Street analysts forecast ANIP's revenue for 2026 to be $24,375,940,216, with the lowest ANIP revenue forecast at $20,826,964,780, and the highest ANIP revenue forecast at $26,057,812,816. On average, 8 Wall Street analysts forecast ANIP's revenue for 2027 to be $27,806,960,320, with the lowest ANIP revenue forecast at $25,048,689,256, and the highest ANIP revenue forecast at $29,600,957,760.
In 2028, ANIP is forecast to generate $30,385,831,640 in revenue, with the lowest revenue forecast at $26,237,212,560 and the highest revenue forecast at $33,525,327,160.